Author: OurCrowd

[Wind Catching Systems in Glass Almanac] Norway stuns with a unique wind turbine wall that could transform renewable energy production

Feb 28, 2025 |

Norway, long known for its leadership in environmental innovation, has just taken a bold step forward in renewable energy with the launch of the Windcatcher project. This groundbreaking concept offers a fresh approach to offshore wind energy by creating a “floating wind wall” made up of several small turbines. The Windcatcher could significantly boost energy efficiency and present a more sustainable alternative to traditional large turbines. But what makes this innovation so exciting, and how could it change the global energy landscape? Read...

Read More

[Databricks in PR Newswire] Databricks Achieves FedRAMP High Authorization for AWS GovCloud

Feb 27, 2025 |

SAN FRANCISCO, Feb. 27, 2025 /PRNewswire/ — Amid the growing momentum of its Public Sector business, Databricks, the Data and AI company, announced today that it has received Federal Risk and Authorization Management Program (FedRAMP®) High authorization from the FedRAMP Program Management Office (PMO) for its Data Intelligence Platform on Amazon Web Services (AWS) GovCloud. This authorization builds on the company’s support for Department of Defense (DoD) Impact Level 5 (IL5) Provisional Authorization (PA) and Azure Databricks’ FedRAMP High and IL5 authorizations, demonstrating a continued commitment to meeting the federal government’s requirements for handling highly sensitive Controlled Unclassified Information (CUI). In addition to Databricks’ investments to make its commercial products FedRAMP authorized, the data intelligence leader strengthened its leadership team, hiring Mike Daniels as Vice President and General Manager of Public Sector. Read...

Read More

[MeMed in Business Wire] MeMed BV Proven to Optimize Antibiotic Use, Outperform Standard Care, and Cut Costs in New Studies

Feb 27, 2025 |

ANDOVER, Mass. & HAIFA, Israel–(BUSINESS WIRE)–MeMed, a leader in host-response diagnostics, today announced the publication of three new peer-reviewed studies, reinforcing the real-world clinical and economic impact of MeMed BV, its flagship diagnostic for differentiating between bacterial and viral infections. Conducted across multiple centers in the U.S., Europe, and the U.K., and involving thousands of patients, these independent studies highlight distinct aspects of MeMed BV’s impact, including better antibiotic stewardship, superior performance over the standard of care, and reduced healthcare costs. Read more...

Read More